Jiangsu Kanion Pharmaceutical Co Ltd (600557) - Total Liabilities
Based on the latest financial reports, Jiangsu Kanion Pharmaceutical Co Ltd (600557) has total liabilities worth CN¥1.83 Billion CNY (≈ $267.42 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 600557 cash generation efficiency to assess how effectively this company generates cash.
Jiangsu Kanion Pharmaceutical Co Ltd - Total Liabilities Trend (1999–2024)
This chart illustrates how Jiangsu Kanion Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 600557 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Jiangsu Kanion Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Kanion Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inner Mongolia ERDOS Resources Co Ltd B
SHG:900936
|
China | $22.44 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥852.18 Million |
|
B.Grimm Power Public Company Limited
BK:BGRIM
|
Thailand | ฿130.75 Billion |
|
Netcare
JSE:NTC
|
South Africa | ZAC18.24 Billion |
|
Wuxi Online Offline Communication Information Technology Co. Ltd.
SHE:300959
|
China | CN¥184.80 Million |
|
SUFA Technology Industry Co Ltd CNNC
SHE:000777
|
China | CN¥1.42 Billion |
|
Lindblad Expeditions Holdings Inc
NASDAQ:LIND
|
USA | $1.11 Billion |
Liability Composition Analysis (1999–2024)
This chart breaks down Jiangsu Kanion Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600557 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Kanion Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Kanion Pharmaceutical Co Ltd (1999–2024)
The table below shows the annual total liabilities of Jiangsu Kanion Pharmaceutical Co Ltd from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.20 Billion ≈ $322.17 Million |
+26.77% |
| 2023-12-31 | CN¥1.74 Billion ≈ $254.14 Million |
-6.72% |
| 2022-12-31 | CN¥1.86 Billion ≈ $272.44 Million |
+20.48% |
| 2021-12-31 | CN¥1.55 Billion ≈ $226.13 Million |
-13.76% |
| 2020-12-31 | CN¥1.79 Billion ≈ $262.19 Million |
-11.45% |
| 2019-12-31 | CN¥2.02 Billion ≈ $296.09 Million |
+18.28% |
| 2018-12-31 | CN¥1.71 Billion ≈ $250.33 Million |
-4.97% |
| 2017-12-31 | CN¥1.80 Billion ≈ $263.43 Million |
+18.10% |
| 2016-12-31 | CN¥1.52 Billion ≈ $223.05 Million |
+6.31% |
| 2015-12-31 | CN¥1.43 Billion ≈ $209.80 Million |
-10.32% |
| 2014-12-31 | CN¥1.60 Billion ≈ $233.94 Million |
+6.75% |
| 2013-12-31 | CN¥1.50 Billion ≈ $219.15 Million |
+1.59% |
| 2012-12-31 | CN¥1.47 Billion ≈ $215.73 Million |
+33.22% |
| 2011-12-31 | CN¥1.11 Billion ≈ $161.93 Million |
+48.90% |
| 2010-12-31 | CN¥743.19 Million ≈ $108.75 Million |
+102.38% |
| 2009-12-31 | CN¥367.23 Million ≈ $53.74 Million |
+3.20% |
| 2008-12-31 | CN¥355.85 Million ≈ $52.07 Million |
-24.90% |
| 2007-12-31 | CN¥473.81 Million ≈ $69.33 Million |
+6.91% |
| 2006-12-31 | CN¥443.19 Million ≈ $64.85 Million |
-16.79% |
| 2005-12-31 | CN¥532.62 Million ≈ $77.94 Million |
+43.61% |
| 2004-12-31 | CN¥370.88 Million ≈ $54.27 Million |
-8.10% |
| 2003-12-31 | CN¥403.56 Million ≈ $59.05 Million |
+335.38% |
| 2002-12-31 | CN¥92.69 Million ≈ $13.56 Million |
-10.54% |
| 2001-12-31 | CN¥103.61 Million ≈ $15.16 Million |
-12.87% |
| 2000-12-31 | CN¥118.92 Million ≈ $17.40 Million |
+4.46% |
| 1999-12-31 | CN¥113.84 Million ≈ $16.66 Million |
-- |
About Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It also offers medicines in the fields of anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others. In addition, the company provides herb extracts and formula granules, as well as OEM/ODM services. Jiangsu Kanion Pharmaceutical Co.,Ltd. was founded in 1975 a… Read more